KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Goodwill (2016 - 2025)

Historic Goodwill for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $196.2 million.

  • Biomarin Pharmaceutical's Goodwill changed 0.0% to $196.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.2 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $196.2 million for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Goodwill stood at $196.2 million, which was down 0.0% from $196.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Goodwill high stood at $196.2 million for Q1 2021, and its period low was $196.2 million during Q1 2021.
  • Its 5-year average for Goodwill is $196.2 million, with a median of $196.2 million in 2021.
  • Over the last 5 years, Biomarin Pharmaceutical's Goodwill had its largest YoY gain of 0.0% in 2021, and its largest YoY loss of 0.0% in 2021.
  • Biomarin Pharmaceutical's Goodwill (Quarter) stood at $196.2 million in 2021, then changed by 0.0% to $196.2 million in 2022, then changed by 0.0% to $196.2 million in 2023, then changed by 0.0% to $196.2 million in 2024, then changed by 0.0% to $196.2 million in 2025.
  • Its Goodwill stands at $196.2 million for Q3 2025, versus $196.2 million for Q2 2025 and $196.2 million for Q1 2025.